The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial.
Study Goal
The researchers aimed to determine the effects of melatonin on disease severity and sleep quality in children with atopic dermatitis (AD).
Results Summary
Melatonin supplementation significantly improved disease severity (SCORAD and objective SCORAD indices), serum total IgE levels, and sleep quality (CSHQ scores), but had no significant impact on pruritus, hs-CRP, sleep-onset latency, total sleep time, weight, or BMI.
Population
Children aged 6-12 years diagnosed with atopic dermatitis.
Effective Dosage
6 mg/d melatonin
Duration
6 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin supplementation | decrease | SCORAD index | children diagnosed with atopic dermatitis (AD) | β -3.55; 95% CI, -6.11, -0.98; P = 0.007 | significantly improved | #1 |
melatonin supplementation | decrease | objective SCORAD index | children diagnosed with atopic dermatitis (AD) | β -3.23; 95% CI, -5.08, -1.38; P = 0.001 | significantly improved | #2 |
melatonin supplementation | decrease | serum total IgE levels | children diagnosed with atopic dermatitis (AD) | β -153.94 ku/L; 95% CI, -260.39, -47.49; P = 0.005 | significantly improved | #3 |
melatonin supplementation | decrease | CSHQ scores | children diagnosed with atopic dermatitis (AD) | β -2.55; 95% CI, -4.34, -0.75; P = 0.006 | significantly improved | #4 |
melatonin | no change | pruritus scores | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #5 |
melatonin | no change | high-sensitivity C-reactive protein (hs-CRP) | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #6 |
melatonin | no change | sleep-onset latency | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #7 |
melatonin | no change | total sleep time | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #8 |
melatonin | no change | weight | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #9 |
melatonin | no change | BMI | children diagnosed with atopic dermatitis (AD) | no significant change | had no significant impact | #10 |
BACKGROUND: The aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis (AD). METHODS: This randomized, double-blinded, placebo-controlled trial was conducted by recruiting 70 patients, aged 6-12 years, who had been diagnosed with AD. Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis (SCORAD) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire (CSHQ). RESULTS: Following 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (β -3.55; 95% CI, -6.11, -0.98; P = 0.007), objective SCORAD index (β -3.23; 95% CI, -5.08, -1.38; P = 0.001), serum total IgE levels (β -153.94 ku/L; 95% CI, -260.39, -47.49; P = 0.005), and CSHQ scores (β -2.55; 95% CI, -4.34, -0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high-sensitivity C-reactive protein (hs-CRP), sleep-onset latency, total sleep time, weight, and BMI compared with placebo. CONCLUSIONS: Overall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD.